Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Triple Negative Breast Neoplasms × Epirubicin × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Non-Muscle Invasive Bladder Neoplasms 1 Breast Neoplasms 1

Interventions

pembrolizumab 20 Specimen Handling 12 Paclitaxel 11 Magnetic Resonance Spectroscopy 11 Carboplatin 11 Biopsy 10 olaparib 7 Gemcitabine 5 Capecitabine 5 130-nm albumin-bound paclitaxel 5 eribulin 4 Taxes 4 Doxorubicin 4 X-Rays 3 Nivolumab 3 Cyclophosphamide 3 Cisplatin 3 tucatinib 2 sargramostim 2 liposomal doxorubicin 2 durvalumab 2 ceralasertib 2 Trastuzumab 2 Standard of Care 2 Platinum 2 Immunoglobulin G 2 Fulvestrant 2 Drug Therapy 2 Docetaxel 2 Colony-Stimulating Factors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06829199 2026-02-19

MK-5890-003

Merck Sharp & Dohme LLC

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡